Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10016884 | 0.94 | TSHR (0.32) | TSHRMEN1KMT2A | |
| SCHEMBL7110870 | 0.84 | TSHR (0.32) | TSHR | |
| SCHEMBL16805864 | 0.84 | TSHR (0.38) | TSHRTGFBR1MTNR1AMTNR1BKDM4E | |
| SCHEMBL339899 | 0.82 | TSHR (0.33) | TSHRMEN1KMT2ATGFBR1THRB | |
| SCHEMBL7115526 | 0.81 | TSHR (0.32) | TSHRKDM4E | |
| SCHEMBL339382 | 0.80 | TSHR (0.31) | TSHR | |
| SCHEMBL24513273 | 0.80 | TGFBR1 (0.37) | TSHRMEN1KMT2ATGFBR1MTNR1A | |
| SCHEMBL7110877 | 0.79 | — | — | |
| SCHEMBL8447931 | 0.79 | MTNR1A (0.33) | TSHRTGFBR1MTNR1AMTNR1BMAPT | |
| SCHEMBL9399525 | 0.79 | TSHR (0.34) | TSHRTGFBR1MTNR1AMTNR1BTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12138274-B2 | Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2024-11-12 | — | — | US | disclosed |
| US-20130251778-A1 | MEDICAL DEVICES FOR THERAPEUTIC AGENT DELIVERY WITH POLYMERIC REGIONS THAT CONTAIN COPOLYMERS HAVING BOTH SOFT SEGMENTS AND UNIFORM LENGTH HARD SEGMENTS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| EP-1979014-B1 | MEDICAL DEVICES FOR THERAPEUTIC AGENT DELIVERY WITH POLYMERIC REGIONS THAT CONTAIN COPOLYMERS HAVING BOTH SOFT SEGMENTS AND UNIFORM LENGTH HARD SEGMENTS | BOSTON SCIENT LTD (BB) | 2013-07-03 | — | — | EP | disclosed |
| US-8440214-B2 | Medical devices for therapeutic agent delivery with polymeric regions that contain copolymers having both soft segments and uniform length hard segments | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120015034-A1 | TEMPERATURE SENSITIVE POLYMERS | UNIVERSITEIT UTRECHT (NL) | 2012-01-19 | — | — | US | disclosed |
| EP-1979014-A2 | MEDICAL DEVICES FOR THERAPEUTIC AGENT DELIVERY WITHOUT POLYMERIC REGIONS THAT CONTAIN COPOLYMERS HAVINT BOTH SOFT SEGMENTS AND UNIFORM LENGHT HARD SEGMENTS | Boston Scientific Scimed, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7425581-B2 | Temperature sensitive polymers | UNIVERSITEIT UTRECHT | 2008-09-16 | — | — | US | disclosed |
| WO-2007089435-A2 | MEDICAL DEVICES FOR THERAPEUTIC AGENT DELIVERY | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070178136-A1 | Medical devices for therapeutic agent delivery with polymeric regions that contain copolymers having both soft segments and uniform length hard segments | BOSTON SCIENTIFIC SCIMED, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015034-A1 | TEMPERATURE SENSITIVE POLYMERS | LCT, LDHA, LDHB | TSHR 4451/4885MEN1 3434/4885KMT2A 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.